• Go to navigation
  • Go to content
AstraZeneca

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca United States

Main navigation

  • Home
  • Our medicines
  • Diseases and conditions
  • Community support
  • Help affording your medicines
  • Research & development
  • Healthcare professionals
  • Careers
  • About AstraZeneca US
    • Investors
    • Our company
    • AZ on the issues
    • Responsible business
    • Newsroom
      • Media resources
      • All news
      • Corporate news
      • Financial news
      • Product news
      • Research news
    • US web sites
    • Contact us

You are here

  • Home
  • About AstraZeneca US
  • Newsroom
  • Research news

The following shows headlines of all research-related news articles published within 12-months, starting from most recent.

  • Pages
  • 1
  • 2
  • Next

Date

    • Nov 19, 2009
    • AstraZeneca submits US New Drug Application for ticagrelor (BRILINTA™), an investigational antiplatelet agent  
    • Nov 18, 2009
    • Results from two Phase II trials add to understanding of ticagrelor (BRILINTA™) and how it works in the body  
    • Nov 15, 2009
    • Ticagrelor (BRILINTA™) demonstrated greater efficacy over clopidogrel in the most urgent clinical setting: Patients with ST-Segment Elevation Myocardial Infarction and planned Percutaneous Coronary Intervention (PCI)  
    • Oct 28, 2009
    • Patients taking VIMOVO showed improved UGI tolerability assessments as compared to EC naproxen  
    • Oct 27, 2009
    • Phase 2 data from oral NKTR-118 presented at American College of Gastroenterology in San Diego  
    • Oct 19, 2009
    • Patients taking VIMOVO™ showed a decrease in incidence of NSAID-associated ulcers  
    • Sep 24, 2009
    • Ticagrelor reduced cardiovascular deaths and heart attacks in ACS patients undergoing heart procedures: New data from PLATO trial  
    • Aug 31, 2009
    • AstraZeneca announces FDA acceptance of New Drug Application for VIMOVO  
    • Aug 30, 2009
    • Phase III head to head trial showed ticagrelor reduced cardiovascular death and heart attacks over clopidogrel in acute coronary syndromes patients  
    • Aug 4, 2009
    • Project Zero Delay accelerates drug’s path to clinical trial  
  • Pages
  • 1
  • 2
  • Next

Page tools

  • Print
  • Bookmark this page
  • Subscribe to RSS news feed

Follow us on Twitter

Follow AstraZenecaUS on Twitter

Legal notices

  • Legal Information
  • Privacy Statement
  • © AstraZeneca 2009